Autoimmune disorders of the neuromuscular junction such as myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) cause fatigable muscle weakness. Patients who are refractory to standard immunosuppressive regimens are sometimes treated with rituximab (RTX), but published evidence for its efficacy has been inconsistent. The authors performed a retrospective single-center cohort analysis to assess real-world clinical course and side effects associated with RTX in MG and LEMS patients treated between 2011 and 2021.
The study included all patients at the center diagnosed with MG (n = 64) or LEMS (n = 5) who received RTX during the 2011–2021 period. The report is based on routine clinical data abstracted retrospectively. The cohort explicitly included patients with thymoma-associated MG.
Clinical outcomes were evaluated using the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS), frequency of rescue therapies, occurrence of myasthenic crises, and median daily steroid dose. Outcomes were reported at baseline, at 1-year follow-up, and at 2-year follow-up where available.
The authors report that MGFA-PIS findings showed improvement at both 1-year and 2-year follow-up compared with baseline, consistent with a stabilized or improved clinical course after initiation of RTX. Specific categorical MGFA-PIS breakdowns or absolute counts by category beyond the statement of overall improvement were not provided in the source abstract.
The frequency of rescue therapies decreased after RTX. Incidence rates of rescue therapies per 100 person-months (95% CI) were reported as:
These reductions indicate fewer rescue interventions were required in the first and second years after RTX treatment compared with the baseline period.
The number of patients without myasthenic crises within one year increased after RTX. At baseline, 49 patients (86.0%) had not experienced a myasthenic crisis within one year; at 1-year follow-up this figure rose to 55 patients (96.5%). The source reports these proportions but does not provide individual patient timelines or detailed crisis severity data.
Median daily steroid dose decreased over time following RTX initiation. Reported median (IQR) prednisone-equivalent doses were:
This pattern suggests a clinically meaningful reduction in systemic steroid exposure in the year after RTX and that the reduction was maintained at two years for those followed.
The study specifies inclusion of patients with thymoma-associated MG and reports that RTX was associated with clinical stabilization and decreased steroid use across the sampled population, including these patients. The source does not provide separate subgroup outcome statistics for thymoma-associated cases in the abstracted content.
The study collected clinical course and side-effect data. However, specific adverse event rates, types, or severity breakdowns were not reported in the abstracted material provided here. Ethical approval constraints currently prevent public sharing of raw data; the corresponding author will consider data requests with a scientific rationale and in accordance with Charité data access policies.
Ethics approval for the retrospective study was granted by the ethics committee of Charité – University Medical Center Berlin (EA1/260/19). Under the approved protocol and applicable law, informed consent was not required for this retrospective analysis. The study adhered to the Declaration of Helsinki, the German Federal Data Protection Act, the EU General Data Protection Regulation, and reporting standards consistent with the STROBE statement.
Several authors declared relationships with pharmaceutical companies, including honoraria, travel support, advisory roles, and institutional research funding. The abstracted source lists these competing interest statements in detail. All other authors reported no conflicts.
In this retrospective single-center cohort of 69 patients with autoimmune myasthenic syndromes treated with rituximab between 2011 and 2021, RTX use was associated with improved MGFA-PIS at 1 and 2 years, lower incidence rates of rescue therapies, an increased proportion of patients free of myasthenic crises at one year, and reduced median daily steroid doses. The data indicate that therapeutic benefit was apparent within the first year and persisted through two years among patients followed. Detailed adverse event data and patient-level results were not reported in the provided abstract; raw data are subject to ethical restrictions and may be available from the corresponding author on request and review.